Lenvatinib + Transarterial Chemoembolization (TACE) Effective for Liver Cancer?

On August 3, 2022, Zhenwei Peng and colleagues from The First Affiliated Hospital of Sun Yat-sen University published the effectiveness and safety results of the LAUNCH Phase III clinical trial in the medical journal "Journal of Clinical Oncology." The trial focused on the use of Lenvatinib + TACE as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC).

This randomized, open-label, multicenter Phase III trial included 338 patients with advanced HCC. Participants were randomly assigned to either the Lenvatinib + TACE group (N=170) or the Lenvatinib monotherapy group (N=168). The primary endpoint was overall survival (OS).

With a median follow-up of 17.0 months, the median overall survival was 17.8 months for the Lenvatinib + TACE group versus 11.5 months for the Lenvatinib monotherapy group. Other evaluation metrics showed that the median progression-free survival (PFS) was 10.6 months for the Lenvatinib + TACE group versus 6.4 months for the Lenvatinib monotherapy group. The objective response rate (ORR) was 54.1% for the combination group compared to 25.0% for the monotherapy group.

Based on the results of the LAUNCH trial, Zhenwei Peng and others stated that Lenvatinib + TACE as a first-line treatment improved overall survival in patients with advanced HCC and is expected to become a new treatment option for this patient population.

Source: https://ascopubs.org/doi/10.1200/JCO.22.00392

• Clinical Trial Drugs

  (Lung Cancer) Phase II Clinical Trial Results of Topotecan and Topotecan + Berzosertib Treatment. (Lung Cancer) Is Enhertu Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is the Anti-B7-H3 Antibody Drug DS-7300 Effective?

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4